For International Audiences: The REDUCER I trial demonstrated #ShockwaveReducer#'s real-world impact on patients, with the following benefits at one year:​ ➡️ 66% decrease in total number of emergency department visits in the year after implantation​ ➡️ 71% ≥1 CCS improvement ​ ➡️ 26% ≥2 CCS improvement​ Learn more: Watch the study's lead investigator, Dr Stefan Verheye, discuss the 12-month results: Verheye S. et al. European Heart Journal. (2024) Vol 45 (Suppl 1)​ Safety info link in Bio. CAUTION: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada.

For International Audiences: COSIRA was the first randomized sham-controlled trial studying the use of #ShockwaveReducer# for refractory angina.​ This pivotal trial demonstrated that patients who received Shockwave Reducer achieved a statistically significant improvement in angina symptoms and quality of life compared to patients in the sham control group. ​ Explore the COSIRA results:  Verheye S. et al. Coronary sinus reducer for treatment of refractory angina: the COSIRA trial. N Engl J Med. 2015;372:519-27.​ Safety Info: ​ CAUTION: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada.

For International Audiences: Patients with diabetes often represent a more complex population, but REDUCER I showed that #ShockwaveReducer# delivers angina relief equally for patients suffering from diabetes.​ The trial demonstrated that device implantation was safe and just as effective at improving angina symptoms and quality of life in patients with and without diabetes.​ Explore the REDUCER I Diabetes Sub-Analysis:  de Silva, R. Results from the REDUCER-I Study. ESC 2025​ Safety Info: ​ CAUTION: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada.

For International Audiences: Angina treatment that's proven to provide relief. The ORBITA-COSMIC RCT showed that #ShockwaveReducer# improved angina symptoms and quality of life compared to placebo. Dig into the results to learn more.​ Angina relief is here. See the proof:  Foley MJ, Rajkumar CA, Ahmed‑Jushuf F, et al. Coronary sinus Reducer for the treatment of refractory angina (ORBITA‑COSMIC): a randomized, placebo‑controlled trial. Lancet. 2024;403(10436):1543‑1553.​ ​ Safety Info: ​ CAUTION: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada.

For International Physicians: Refractory angina is often not the end of the road. It’s about understanding the underlying mechanisms and identifying patients who do have new therapeutic options. Despite optimal therapy, many patients continue to experience debilitating symptoms. Innovative approaches like the #ShockwaveReducer# are helping redefine what’s possible. This was a key theme in the discussion between Dr Tim van de Hoef (@drTPH) and Dr Tommaso Gori (@tommasoggori) at EuroPCR 2026, highlighting the importance of better patient identification and how a shift in perspective can open new possibilities, including the #ShockwaveReducer#. Watch the video to explore how the understanding of refractory angina is evolving and why it may not be as “refractory” as we think: Safety info link in Bio. CAUTION: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada.